Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 445 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Obesity/Therapy
Interventions: Semaglutide 1.7mg subcutaneous, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes, Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 31
States / cities: Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Concord, California • Sacramento, California + 17 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 56
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Interventions: Semaglutide, Berobenatide, Tirzepatide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Canoga Park, California • Los Angeles, California + 20 more

Conditions: Physical Activity, Sedentary Lifestyle, Metabolism, Energy Balance
Interventions: Data Collection Procedures; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 14 Years to 18 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25,358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Trevose, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: IcoSema, Semaglutide 1 mg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 76
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Semaglutide (Rybelsus®), Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Breast Cancer Risk
Interventions: tirzepatide; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Kansas City, Kansas • Westwood, Kansas

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Meridian, Idaho + 6 more

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Insulin Lispro (U100); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more

Conditions: Obesity or Overweight
Interventions: Maridebart Cafraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 56
States / cities: Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 48 more

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO6807952, liraglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Interventions: tirzepatide, Standard of Care; Drug · Behavioral
Lead sponsor: Marlene Starr; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions: Tirzepatide; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Aspiration
Interventions: GLP-1 RA users with prolonged fasting instructions, GLP-1 RA users with standard NPO instructions; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity & Overweight
Interventions: Tirzepatide, Exercise; Drug · Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus
Interventions: Liraglutide, Golimumab; Drug
Lead sponsor: Carla Greenbaum, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Seattle, Washington

Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine); Drug
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 7,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more

Conditions: Healthy
Interventions: Tirzepatide, EE/NGM; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obese Adults
Interventions: Placebo, Tirzepatide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Weight Gain
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 14
States / cities: Los Angeles, California • Sacramento, California • Wilmington, Delaware + 11 more

Conditions: Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

2024 Tirzepatide-Bariatric Surgery

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide